Elranatamab in R/R Multiple Myeloma
Condition(s):Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple MyelomaLast Updated:November 21, 2023Not yet recruiting
Hide Studies Not Open or Pending
Condition(s):Refractory Multiple Myeloma; Relapse Multiple Myeloma; Multiple MyelomaLast Updated:November 21, 2023Not yet recruiting
Condition(s):Extranodal NK T Cell Lymphoma; NK-Cell LeukemiaLast Updated:July 12, 2023Recruiting
Condition(s):Renal Impairment; Multiple MyelomaLast Updated:March 10, 2023Terminated
Condition(s):Adult B Acute Lymphoblastic LeukemiaLast Updated:November 13, 2020Unknown status
Condition(s):Recurrent Multiple Myeloma; Refractory Multiple MyelomaLast Updated:January 17, 2024Recruiting
Condition(s):Multiple MyelomaLast Updated:December 19, 2022Terminated
Condition(s):Multiple Myeloma in RelapseLast Updated:February 13, 2024Recruiting
Condition(s):Multiple MyelomaLast Updated:August 16, 2021Completed
Condition(s):Relapsed or Refractory Multiple MyelomaLast Updated:November 13, 2020Unknown status
Condition(s):Refractory Indolent Adult Non-Hodgkin LymphomaLast Updated:November 13, 2020Unknown status
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.